Chronic Hepatitis C Treatment Submitted for Labeling Update
About 97% of patients treated with SMV/SOF for 12 weeks (n=150/155) achieved SVR12, which was superior to the SVR12 rate of 87% among the historical control.
All articles by Mital Patel, PharmD
Single Dalvance Dose Effective For ABSSSI
Actavis announced results for its Phase 3 DUR001-303 study of single dose Dalvance for the treatment of acute bacterial skin and skin structure infections.
Ebola Virus One-Step Test Kits Recalled By The FDA
The FDA has issued a Class 1 recall for the Ebola Virus One-Step Test Kits (LuSys Laboratories).
Ebola Vaccine Provokes Immune Response
Researchers have published results from the first phase 1 trial of an Ebola vaccine developed based on the 2014 Zaire Guinea Ebola strain.
